Bristol-myers Squibb Pharma Company

Bristol-myers Squibb Compnay

Christopher D McClung

Albert Jean Robichaud

Taekyu Lee

Ian S Mitchell

Wenting Chen

Wei Deng

David M Zawrotny

Michael G Yang

Simon Nicolas Haydar

Emilie J Calvello

Emile J B Calvello

Parthasarathl Rajagopalan

Emilie J B Calvello

The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Substituted heterocycle fused gamma-carbolines

The present invention is directed to certain novel compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Substituted heterocycle fused &#x3b3;-carbolines

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Growing community of inventors

Chicago, IL, United States of America

Christopher D McClung